Plunkett Research Online: Aurinia Pharmaceuticals

AURINIA PHARMACEUTICALS (AUPH:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FS.....



Aurinia Pharmaceuticals
Ticker: AUPH
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 250 708-4272
Fax: 250 744-2498
Address: 4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription

Dennis BourgeaultCFO
Neil SolomonsChief Medical Officer
See More
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FS.....See More See More

Auditor: PricewaterhouseCoopers LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: